



# Biotech Daily

Thursday June 4, 2015

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: ANALYTICA UP 20%, PRIMA DOWN 9.5%**
- \* **BIOTA TAKES ANACONDA FOR AP611074 FOR ANO-GENITAL WARTS**
- \* **3D SIGNS MACH7 TELSTRA HEALTH DEAL**
- \* **ANALYTICA CLAIMS PERICOACH 'ENCOURAGING EARLY SALES'**
- \* **PRIMA RECOMPILES WITH NASDAQ MINIMUM PRICE RULE**
- \* **ONCOSIL APPOINTS DR ASHISH SOMAN CHIEF MEDICAL OFFICER**

## MARKET REPORT

The Australian stock market fell 1.42 percent on Thursday June 4, 2015 with the S&P ASX 200 down 79.3 points to 5,504.3 points.

Ten of the Biotech Daily Top 40 stocks were up, 20 fell, six traded unchanged and four were untraded.

Analytica was the best, up 0.2 cents or 20 percent to 1.2 cents with 16.8 million shares traded.

Antisense and Bionomics climbed nine percent or more; Oncosil and Viralytics were up four percent or more; Biotron and Living Cell were up more than three percent; Nanosonics rose 2.1 percent; Anteo and Reva were up more than one percent; with Resmed up 0.7 percent.

Prima led the falls, down 0.9 cents or 9.5 percent to 8.6 cents with 25.6 million shares traded.

Atcor lost seven percent; Optiscan, Sirtex, Starpharma and Universal Biosensors lost more than five percent; Admedus, Avita, Cellmid, IDT and Tissue Therapies fell four percent or more; Acrux, Cochlear, Compumedics, Genetic Technologies and Prana shed more than two percent; Actinogen, Clinuvel, CSL, Medical Developments and Neuren were down more than one percent; with Mesoblast down 0.3 percent.

### BIOTA PHARMACEUTICALS

Biota says it has completed the acquisition of the Paris, France-based Anaconda Pharma and will proceed to a phase II trial of AP611074 for ano-genital warts late this year.

Biota said that AP611074 was a direct-acting antiviral in clinical development for the treatment of condyloma, or ano-genital warts, as well as the orphan disease recurrent respiratory papillomatosis, both of which were caused by human papillomavirus (HPV) types 6 and 11.

Biota chief executive officer Dr Joseph Patti said the phase II trial was intended to “validate its favorable local skin tolerability profile and antiviral activity”.

“AP611074 is uniquely positioned to significantly improve the treatment paradigm for ano-genital warts, the most frequently sexually-transmitted viral disease worldwide and [respiratory papillomatosis], a rare condition in which epithelial tumor-like lesions grow on the larynx,” Dr Patti said.

On the Nasdaq, Biota fell 1.0 US cent or 0.47 percent to \$US2.14 (\$A2.75 equivalent to 34.4 cents prior to the Nabi merger, when it was trading around \$A1.00) with 78,138 shares traded.

### 3D MEDICAL

3D Medical says Telstra Corp division Telstra Health will resell its Mach7 Technologies image management products and develop an image and data management service.

3D said it had exclusive reseller rights in Australia and New Zealand to the South Burlington, Vermont-based Mach7 Technologies, which developed image management products for hospitals, radiology clinics and other health service providers.

The company said the Telstra agreement formalized a letter of intent announced in March (BD: Mar 11, 2015).

3D said that the Agreement allowed the supply of specific Telstra Health products to 3D Medical's new and existing customers, with the commercial release planned to begin by September 2015.

3D chief executive officer Max Ghobrial said the Telstra contract included the company's Vendor Neutral Archive product, which had “the potential to make a significant impact on how patient data can be stored and shared in Australia”.

3D fell half a cent or 4.35 percent to 11 cents with 3.8 million shares traded.

### ANALYTICA

Analytica says that sales of its Pericoach intra-vaginal pelvic floor monitor and strengthening system have increased through the five months to May 31, 2015.

Analytica said that sales increased from about 110 units at the beginning of 2015 to a total of about 350 units for the five months to May 31, 2015.

Analytica chief executive officer Geoff Daly told Biotech Daily that the full retail price of the units was \$298 each with annual fees after the first 12 months of \$50 a year.

Mr Daly said that the units sold so far to clinicians and patients included various discounts. A graph provided by Analytica indicated a sharp increase in sales to patients from April with a leveling of sales to clinicians.

In a media release, the company said that the Pericoach had “encouraging early sales results” and was approved in Australia, the US and the EU.

Analytica was up 0.2 cents or 20 percent to 1.2 cents with 16.8 million shares traded.

### PRIMA BIOMED

Prima says that having maintained a Nasdaq share price at or above \$US1.00 for 10 consecutive business days it has regained compliance with the minimum bid price rule.

Prima said its shares would remain listed on the Nasdaq.

Prima fell 0.9 cents or 9.5 percent to 8.6 cents with 25.6 million shares traded.

### ONCOSIL MEDICAL

Oncosil says it has appointed Dr Ashish Soman as its chief medical officer.

Oncosil said that Dr Soman was a former Astrazeneca medical director for Australia with more than 24 years experience and he would play a key role in the EU and US regulatory approvals process and commercialization of the Oncosil localized radiation treatment for pancreatic and primary liver cancer.

The company said that previously Dr Soman was with Sanofi-Aventis Australia-New Zealand and Roche Products UK.

Oncosil said that Dr Soman held a Bachelor of Medicine and Surgery from the University of London, and a Masters of Business Administration from Imperial College, London.

Oncosil was up half a cent or 4.35 percent to 12 cents with 1.25 million shares traded.